Literature DB >> 7001862

The effect of beta-blockade on glucose tolerance and insulin release in adult diabetes.

G Holm, S Johansson, A Vedin, C Wilhelmsson, U Smith.   

Abstract

Blood glucose and plasma insulin levels were studied in ten adult diabetics treated in a cross-over fashion for at least three weeks with alprenolol, a non-selective beta-blocker, or with metoprolol, a cardioselective beta 1-blocker. Dietary intake was controlled three days prior to the study which comprised both i.v. and oral glucose tolerance tests. Mean fasting blood glucose levels were significantly higher on alprenolol than on metoprolol. The increase in fasting blood glucose was particularly pronounced in two patients. In these subjects the glucose tolerance following both an i.v. and an oral glucose load was reduced when treatment was switched from metoprolol to alprenolol. Lower plasma insulin levels in response to glucose were also found in these patients on alprenolol than on metoprolol. The mean insulin levels for all ten patients did not differ significantly between the two treatment periods. These data show that treatment with a non-selective beta-blocker can in some patients cause a considerable deterioration of the glucose tolerance, presumably due to inhibition of insulin release.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7001862     DOI: 10.1111/j.0954-6820.1980.tb01175.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  15 in total

1.  Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non-insulin-dependent diabetics.

Authors:  B Ehmer; R van der Does; J Rudorf
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 2.  Recent Advances in Pharmacological Management of Hypertension in Diabetic Patients with Nephropathy : Effects of Antihypertensive Drugs on Kidney Function and Insulin Sensitivity.

Authors:  Tsuneharu Baba; Takashi Ishizaki
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

3.  Effects of chronic metoprolol treatment on glucose tolerance after myocardial infarction.

Authors:  G Olsson; N Rehnqvist
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  The influence of beta-adrenoceptor blocking drugs with and without intrinsic sympathomimetic activity on the hormonal responses to hypo- and hyperglycaemia.

Authors:  K J Schlüter; W H Aellig; K G Petersen; H C Rieband; A Wehrli; L Kerp
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

Review 5.  The choice of antihypertensive therapy in the diabetic patient.

Authors:  A D Struthers
Journal:  Postgrad Med J       Date:  1985-07       Impact factor: 2.401

Review 6.  Report of the Canadian Hypertension Society Consensus Conference: 5. Hypertension and diabetes.

Authors:  K G Dawson; J K McKenzie; S A Ross; J L Chiasson; P Hamet
Journal:  CMAJ       Date:  1993-09-15       Impact factor: 8.262

Review 7.  Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2.

Authors:  J E Jackson; R Bressler
Journal:  Drugs       Date:  1981-10       Impact factor: 9.546

8.  Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.

Authors:  T Pollare; H Lithell; I Selinus; C Berne
Journal:  BMJ       Date:  1989-04-29

9.  Plasma insulin levels and beta-adrenoceptor antagonists. The effects of cardioselective and non-cardioselective beta-adrenoceptor antagonists with and without intrinsic sympathomimetic activity on basal insulin level and insulin level after glucose stimulation in normoglycemic dogs.

Authors:  W Conca; A Beck; S Bacher; G Raberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-07       Impact factor: 3.000

10.  Plasma insulin levels and beta-adrenoceptor antagonists. Relevance of the steric configuration of beta-adrenoceptor antagonists to their effect on glucose tolerance.

Authors:  A Beck; W Conca; S Bacher; G Raberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.